3f78: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
==Crystal structure of wild type LFA1 I domain complexed with isoflurane==
==Crystal structure of wild type LFA1 I domain complexed with isoflurane==
<StructureSection load='3f78' size='340' side='right' caption='[[3f78]], [[Resolution|resolution]] 1.60&Aring;' scene=''>
<StructureSection load='3f78' size='340' side='right' caption='[[3f78]], [[Resolution|resolution]] 1.60&Aring;' scene=''>
Line 6: Line 7:
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[3f74|3f74]]</td></tr>
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[3f74|3f74]]</td></tr>
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">CD11A, integrin LFA1, ITGAL ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">CD11A, integrin LFA1, ITGAL ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3f78 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3f78 OCA], [http://pdbe.org/3f78 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=3f78 RCSB], [http://www.ebi.ac.uk/pdbsum/3f78 PDBsum]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3f78 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3f78 OCA], [http://pdbe.org/3f78 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=3f78 RCSB], [http://www.ebi.ac.uk/pdbsum/3f78 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=3f78 ProSAT]</span></td></tr>
</table>
</table>
== Function ==
== Function ==
Line 29: Line 30:
</div>
</div>
<div class="pdbe-citations 3f78" style="background-color:#fffaf0;"></div>
<div class="pdbe-citations 3f78" style="background-color:#fffaf0;"></div>
==See Also==
*[[Integrin|Integrin]]
== References ==
== References ==
<references/>
<references/>

Revision as of 12:27, 25 October 2017

Crystal structure of wild type LFA1 I domain complexed with isofluraneCrystal structure of wild type LFA1 I domain complexed with isoflurane

Structural highlights

3f78 is a 3 chain structure with sequence from Human. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Ligands:, ,
Gene:CD11A, integrin LFA1, ITGAL (HUMAN)
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Function

[ITAL_HUMAN] Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. It is involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes.

Evolutionary Conservation

Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf.

Publication Abstract from PubMed

Volatile anesthetics (VAs), such as isoflurane, induce a general anesthetic state by binding to specific targets (i.e., ion channels) in the central nervous system (CNS). Simultaneously, VAs modulate immune functions, possibly via direct interaction with alternative targets on leukocytes. One such target, the integrin lymphocyte function-associated antigen-1 (LFA-1), has been shown previously to be inhibited by isoflurane. A better understanding of the mechanism by which isoflurane alters protein function requires the detailed information about the drug-protein interaction at an atomic level. Here, we describe the crystal structure of the LFA-1 ligand-binding domain (I domain) in complex with isoflurane at 1.6 A. We discovered that isoflurane binds to an allosteric cavity previously implicated as critical for the transition of LFA-1 from the low- to the high-affinity state. The isoflurane binding site in the I domain involves an array of amphiphilic interactions, thereby resembling a "common anesthetic binding motif" previously predicted for authentic VA binding sites. These results suggest that the allosteric modulation of protein function by isoflurane, as demonstrated for the integrin LFA-1, might represent a unified mechanism shared by the interactions of volatile anesthetics with targets in the CNS.

Crystal structure of isoflurane bound to integrin LFA-1 supports a unified mechanism of volatile anesthetic action in the immune and central nervous systems.,Zhang H, Astrof NS, Liu JH, Wang JH, Shimaoka M FASEB J. 2009 Aug;23(8):2735-40. Epub 2009 Mar 30. PMID:19332643[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

References

  1. Zhang H, Astrof NS, Liu JH, Wang JH, Shimaoka M. Crystal structure of isoflurane bound to integrin LFA-1 supports a unified mechanism of volatile anesthetic action in the immune and central nervous systems. FASEB J. 2009 Aug;23(8):2735-40. Epub 2009 Mar 30. PMID:19332643 doi:10.1096/fj.09-129908

3f78, resolution 1.60Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA